Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.96
-0.34 (-5.40%)
At close: May 15, 2026, 4:00 PM EDT
6.08
+0.12 (2.01%)
After-hours: May 15, 2026, 7:58 PM EDT
Taysha Gene Therapies Revenue
Taysha Gene Therapies had revenue of $7.47M in the twelve months ending March 31, 2026, up 3.42% year-over-year. In the year 2025, Taysha Gene Therapies had annual revenue of $9.77M with 17.28% growth.
Revenue (ttm)
$7.47M
Revenue Growth
+3.42%
P/S Ratio
242.32
Revenue / Employee
$75,465
Employees
99
Market Cap
1.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.77M | 1.44M | 17.28% |
| Dec 31, 2024 | 8.33M | -7.12M | -46.07% |
| Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
| Dec 31, 2022 | 2.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 899.11M |
| Vericel | 292.09M |
| Zymeworks | 81.26M |
| Nurix Therapeutics | 71.78M |
| Viridian Therapeutics | 70.92M |
| Agios Pharmaceuticals | 66.05M |
| uniQure | 18.09M |
| Capricor Therapeutics | 11.13M |
TSHA News
- 9 days ago - Taysha Gene Therapies reports Q1 EPS (12c), consensus (10c) - TheFly
- 9 days ago - Taysha Gene Therapies Earnings Call Transcript: Q1 2026 - Transcripts
- 9 days ago - Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 14 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 - GlobeNewsWire
- 18 days ago - Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting - GlobeNewsWire
- 4 weeks ago - Unusually active option classes on open April 16th - TheFly
- 5 weeks ago - Taysha Gene Therapies price target raised to $17 from $14 at Canaccord - TheFly